<DOC>
	<DOCNO>NCT02144948</DOCNO>
	<brief_summary>This pilot study investigate effect e.-coli-nissle support therapy antidiabetic standard care patient diabetes mellitus type II</brief_summary>
	<brief_title>Investigation Effect E.-Coli-Nissle Supporting Therapy Standard Care Diabetes Mellitus Type II</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>diabetes mellitus type 2 ; HbA1c &gt; 7 % ( stable für 6 month , max . variation 0,5 % ) stable oral antidiabetic therapy 6 month Metformin , Vildagliptin , Gliniden without oral Antidiabetics age 45 &lt; 80 year ( men woman ) Myocardial infarction stroke within last 5 year Therapy acarbose Acute peripheral arterial disease within last 12 month Instable metabolic situation Uncontrolled hypertension BodyMassIndex ≥ 35 kg/m² Smokers Daily consumption probiotic food Malignant disease within last 5 year Status post transplantation Immunosuppressive therapy within last 3 month Therapy antibiotic Macroalbuminuria Severe liver disease</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>diabetes</keyword>
</DOC>